By Suherman Candra Maholtra 
In a significant advancement for global public health, researchers at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health have announced the development of an experimental therapeutic DNA vaccine designed to eradicate the most resilient forms of tuberculosis (TB). Unlike traditional vaccines that are injected into muscle tissue, this novel treatment is administered through the nose, specifically targeting "persister" bacteria—drug-tolerant microbes that frequently survive standard antibiotic courses and lead to life-threatening relapses. The study, recently published in the Journal of Clinical Investigation, provides a potential roadmap for shortening the grueling treatment regimens currently required to manage the disease.
Tuberculosis remains a formidable adversary for modern medicine, having plagued human populations for more than six millennia. Despite the advent of antibiotics in the mid-20th century, TB continues to claim more lives annually than any other single infectious pathogen, with the exception of the peak years of the COVID-19 pandemic. The Johns Hopkins team, led by Styliani Karanika, M.D., an assistant professor of medicine and faculty member of the Johns Hopkins Center for Tuberculosis Research, believes that an immunotherapy-based approach may be the key to finally overcoming the biological defenses of Mycobacterium tuberculosis.
The Global Crisis of Latent and Active Tuberculosis
To understand the necessity of this new vaccine, one must look at the staggering scale of the global TB burden. According to the World Health Organization (WHO) 2024 reports, approximately 2 billion people—one-quarter of the world’s population—carry a latent TB infection. While these individuals do not currently show symptoms and are not contagious, the bacteria remain dormant within their systems, essentially acting as a biological "ticking time bomb" that can transition into active disease if the host’s immune system weakens.
In 2024 alone, more than 10 million people developed active tuberculosis, resulting in 1.2 million deaths. The traditional treatment for active TB is notoriously difficult, requiring patients to adhere to a cocktail of powerful antibiotics for six to nine months. The length of this regimen often leads to poor patient compliance, which in turn fuels the rise of multidrug-resistant TB (MDR-TB). The WHO has repeatedly called for the development of "therapeutic vaccines"—treatments administered to those already infected—to supplement drug therapy, shorten treatment times, and reduce the risk of recurrence.
Targeting the "Persister" Phenomenon
The primary obstacle to curing TB quickly is the existence of "persisters." These are a subset of TB bacteria that, when exposed to the stress of antibiotics or the host’s immune response, enter a state of metabolic dormancy. In this "sleep-like" state, the bacteria become tolerant to drugs that typically target active metabolic processes. Once the antibiotic treatment ends, these persisters can "wake up," replicate, and cause a clinical relapse.
The Johns Hopkins vaccine utilizes a sophisticated DNA-based platform to prevent this cycle. By fusing two specific genes—relMtb and Mip3α—the vaccine trains the immune system to recognize the specific proteins associated with this dormant state. The relMtb gene is responsible for producing the RelMtb protein, which the bacteria use as a survival mechanism during periods of low oxygen or nutrient limitation. By targeting this specific protein, the vaccine essentially strips away the bacteria’s ability to hide from the immune system.
The second component, the Mip3α gene, acts as a homing beacon. It produces a signal that attracts immature dendritic cells. These cells are the "sentinels" of the immune system; they capture foreign proteins and present them to T cells, which then coordinate a targeted destruction of the pathogen. By combining these two genes, the vaccine ensures that the immune system not only recognizes the "hiding" bacteria but also has the necessary cellular machinery in place to attack them.
The Strategic Advantage of Intranasal Delivery
A critical feature of the experimental vaccine is its delivery method. Most vaccines are administered via intramuscular injection, which triggers a systemic immune response throughout the bloodstream. However, TB is primarily a respiratory disease, entering the body and establishing its primary infection site in the lungs.
By delivering the vaccine intranasally, the researchers are able to stimulate mucosal immunity directly in the respiratory tract. "Intranasal delivery focuses vaccination on the respiratory mucosa in the lungs where TB infection occurs," Dr. Karanika explained. This localized approach helps generate long-lasting T-cell immunity within the airways, creating a frontline defense at the point of entry. This is particularly important for generating CD4 (helper T cells) and CD8 (killer T cells) that are specifically "programmed" to patrol the lung tissue.
Efficacy in Preclinical Animal Models
The research team conducted extensive testing in mouse models to evaluate the vaccine’s efficacy when combined with standard treatments. The results were highly encouraging. Mice that received the intranasal DNA vaccine alongside first-line TB drugs cleared the infection significantly faster than those treated with drugs alone. Furthermore, the vaccinated mice showed a marked reduction in lung inflammation and, most importantly, did not experience a relapse after the antibiotic treatment was discontinued.
The study also tested the vaccine in conjunction with the "BPaL" regimen—a potent combination of bedaquiline, pretomanid, and linezolid used to treat highly drug-resistant TB. The vaccine appeared to enhance the effectiveness of these drugs, suggesting that immunotherapy could be a vital tool in the fight against the most difficult-to-treat strains of the disease.
Following the mouse trials, the team moved to a rhesus macaque model. Nonhuman primates are essential for TB research because their immune systems and the way they manifest TB infection closely mirror human biology. The results in macaques confirmed that the vaccine could generate measurable, TB-specific immune responses in both the blood and the lungs. These responses remained stable for at least six months, indicating the potential for durable, long-term protection.
Chronology of Development and Future Research
The development of the Mip3α/relMtb vaccine is the result of years of interdisciplinary collaboration at Johns Hopkins. The timeline of the research reflects a move toward more targeted genetic medicine:
- Identification of relMtb (Early 2010s): Researchers identified the gene responsible for the "stringent response" in TB, which allows the bacteria to enter a persistent state.
- Fusion Gene Engineering (Mid-2010s): The team experimented with fusing bacterial genes with mammalian signaling genes (Mip3α) to enhance dendritic cell recruitment.
- Mouse Efficacy Trials (2018–2022): Extensive testing demonstrated that the vaccine could prevent relapse and reduce inflammation.
- Primate Immunogenicity Study (2023): The vaccine was proven to be safe and immunogenic in rhesus macaques, providing the "translational bridge" needed for human consideration.
- Publication and Patenting (2024): The findings were published in the Journal of Clinical Investigation, and a patent (PCT/US2023/065584) was filed by the inventors.
Despite these successes, Dr. Karanika cautioned that more work is required. While the primate study showed that the vaccine triggers the right immune markers, it did not involve a "challenge" phase where vaccinated monkeys were exposed to live TB. The next step in the research will involve testing the vaccine’s protective efficacy in primates before moving to Phase I human clinical trials.
Public Health and Economic Implications
The potential impact of a successful therapeutic TB vaccine cannot be overstated. From a public health perspective, shortening the treatment duration from six months to perhaps three or four would drastically increase completion rates. In many parts of the world, patients stop taking their medication once they begin to feel better, which is exactly when the "persister" bacteria begin to develop resistance to the drugs.
Economically, the burden of TB is concentrated in low- and middle-income countries. The cost of long-term treatment, combined with the loss of productivity for infected adults, drains billions of dollars from global economies annually. DNA vaccines offer a distinct advantage in these settings: they are generally more stable than traditional protein-based or mRNA vaccines and can be produced relatively efficiently. Because they do not require the same level of ultra-cold-chain storage as some modern vaccines, they are better suited for distribution in rural or resource-limited areas.
Furthermore, the "immunotherapy" approach signals a shift in how we treat chronic infections. By using the body’s own immune system to target specific bacterial states (like dormancy), we reduce the reliance on ever-stronger antibiotics, which in turn slows the evolution of "superbugs."
Conclusion: A New Frontier in Tuberculosis Treatment
The work at Johns Hopkins represents a pivot point in the 6,000-year history of human interaction with tuberculosis. For decades, the medical community relied almost exclusively on chemical agents to kill the bacteria. However, the survival strategies of Mycobacterium tuberculosis have proven to be exceptionally robust.
By integrating genetic engineering, immunology, and a localized delivery system, the Johns Hopkins team has developed a tool that does not just kill the bacteria that are growing, but hunts down the bacteria that are hiding. As the researchers move toward human trials, the global health community watches with cautious optimism. If the results seen in mice and macaques can be replicated in humans, the intranasal DNA vaccine could become a cornerstone of the WHO’s "End TB Strategy," offering hope to millions who currently live under the shadow of this ancient and resilient disease.
The study was supported by various grants from the National Institutes of Health (NIH), including the National Institute of Allergy and Infectious Diseases (NIAID) and the National Cancer Institute (NCI), alongside private support from foundations like the Willowcraft Foundation and the Potts Memorial Foundation. The interdisciplinary nature of the team—spanning medicine, public health, and oncology—underscores the complex, multi-front effort required to finally eradicate one of history’s most persistent killers.
